Remove 2028 Remove Healthcare Remove Pharma
article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. If pharma is a business, they will find a way to develop, buy, or acquire new drugs. healthcare spending will reach $6.2

article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the whole industry is winning praise for co-operation” However, the bump in reputation will be short-lived because companies need to earn the public’s trust every day, and pharma is already damaging their perception with people.

Pharma 186
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

US Healthcare Industry Sectors: Facts, Trends, & Statistics

Medico Reach

Infographic content: The onset of the COVID-19 pandemic has pushed significant growth in the US Healthcare Industry, with 2022 being the year of consumer influence. With higher interoperability levels and significantly better price transparency for medical bills and drugs, the US healthcare industry is dead set on growth.

article thumbnail

Non-Invasive Healthcare Products Buy and Sell

Contrarian Sales Techniques

Non-invasive healthcare products refer to medical devices or technologies that do not require puncturing the skin or entering the body in any way to diagnose, treat, or monitor a health condition. The market for non-invasive healthcare products is expected to grow significantly in the coming years.

article thumbnail

Pharma-biotech partnerships take on new urgency as patent cliffs loom

Clarivate

A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.

Pharma 52
article thumbnail

Growing pains: how the pharmaceutical industry can hire and retain talent during industry boom

pharmaphorum

A new operating model for pharma shifted priorities and forced companies to rethink their organisational strategies. Everything from transitioning to virtual meetings with healthcare providers, to navigating the logistics of supply chain disruptions, has permanently altered pharma operations – many would say for the better.

article thumbnail

Viatris to acquire Oyster Point and Famy Life Sciences

Pharmaceutical Technology

Viatris has signed definitive agreements to acquire Oyster Point Pharma and Famy Life Sciences in a deal totalling nearly $700m-$750m in cash to establish an ophthalmology franchise. Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year.